Kiniksa Pharmaceuticals, Ltd. (KNSA)


-1.37 (-8.11%)
Symbol KNSA
Price $15.53
Beta -0.094
Volume Avg. 0.48M
Market Cap 1.090B
Shares () -
52 Week Range 10.29-20.65
1y Target Est -
DCF Unlevered KNSA DCF ->
DCF Levered KNSA LDCF ->
ROE -46.67% Strong Sell
ROA -55.50% Strong Sell
Operating Margin -
Debt / Equity -2.76% Neutral
P/E 4.79 Buy
P/B -2.22 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest KNSA news

Mr. Sanj K. Patel
NASDAQ Global Select

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.